140 related articles for article (PubMed ID: 32742988)
1. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
2. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study.
Li H; Guo Y; Sun X; Lu Y; Chang S; Wang X; Gao S; Gao C; Zhao T
Front Oncol; 2023; 13():1276037. PubMed ID: 37909023
[TBL] [Abstract][Full Text] [Related]
3. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
[TBL] [Abstract][Full Text] [Related]
5. French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel
Demaziere A; Mourgues C; Lambert C; Trevis S; Bertucat H; Grange I; Pezet D; Sautou V; Jary M; Gagnière J
Ther Adv Med Oncol; 2024; 16():17588359241259635. PubMed ID: 38882442
[TBL] [Abstract][Full Text] [Related]
6. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
Postlewait LM; Ethun CG; Kooby DA; Sarmiento JM; Chen Z; Staley CA; Brutcher E; Adsay V; El-Rayes B; Maithel SK
J Surg Oncol; 2016 Sep; 114(3):336-41. PubMed ID: 27501338
[TBL] [Abstract][Full Text] [Related]
7. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia.
Rogers JE; Mizrahi JD; Shroff RT; Nelson DA; Tu J; Javle MM; Wolff RA; Pant S
J Gastrointest Oncol; 2020 Feb; 11(1):55-60. PubMed ID: 32175105
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
9. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes of adjuvant gemcitabine
Kang S; Yoo C; Lee SH; Oh D; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Kwak BJ; Hong S; Chang HM; Ryoo BY; Kim KP; Kim SC
Ther Adv Med Oncol; 2022; 14():17588359221097190. PubMed ID: 35571606
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.
Zong Y; Peng Z; Wang X; Lu M; Shen L; Zhou J
Cancer Manag Res; 2020; 12():12657-12666. PubMed ID: 33328763
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis.
de Jesus VHF; Riechelmann RP
Ecancermedicalscience; 2021; 15():1276. PubMed ID: 34567261
[TBL] [Abstract][Full Text] [Related]
13. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
de Jong EJM; Janssen QP; Simons TFA; Besselink MG; Bonsing BA; Bouwense SAW; Geurts SME; Homs MYV; de Meijer VE; Tjan-Heijnen VCG; van Laarhoven HWM; Valkenburg-van Iersel LBJ; Wilmink JW; van der Geest LG; Koerkamp BG; de Vos-Geelen J;
Int J Cancer; 2022 May; 150(10):1654-1663. PubMed ID: 34935139
[TBL] [Abstract][Full Text] [Related]
14. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
15. SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment.
Bianconi D; Herac M; Spies D; Kieler M; Brettner R; Unseld M; Fürnkranz K; Famler B; Schmeidl M; Minichsdorfer C; Zielinski C; Heller G; Prager GW
Transl Oncol; 2019 Jan; 12(1):15-23. PubMed ID: 30245304
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study.
Zhang F; Wang Y; Yang F; Zhang Y; Jiang M; Zhang X
Cancer Manag Res; 2022; 14():535-546. PubMed ID: 35173487
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRINOX
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; An C; Park MS; Bang S
World J Gastrointest Oncol; 2020 Feb; 12(2):182-194. PubMed ID: 32104549
[TBL] [Abstract][Full Text] [Related]
18. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy.
Mortier V; Wei F; Pellat A; Marchese U; Dohan A; Brezault C; Barat M; Fuks D; Soyer P; Coriat R
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551662
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus
Tajima H; Makino I; Gabata R; Okazaki M; Ohbatake Y; Shimbashi H; Nakanuma S; Saitoh H; Shimada M; Yamaguchi T; Okamoto K; Moriyama H; Kinoshita J; Nakamura K; Miyashita T; Ninomiya I; Fushida S; Ikeda H; Ohta T
Mol Clin Oncol; 2021 Feb; 14(2):26. PubMed ID: 33414907
[TBL] [Abstract][Full Text] [Related]
20. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
Cheon J; Lee CK; Sang YB; Choi HJ; Kim MH; Ji JH; Ko KH; Kwon CI; Kim DJ; Choi SH; Kim C; Kang B; Chon HJ
Ther Adv Med Oncol; 2021; 13():17588359211035983. PubMed ID: 34394748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
